diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that E. Ralf Schoenbrunner, Ph.D. has been appointed to the position of senior vice president of research and early development. Dr. Schoenbrunner has more than 20 years of experience in the medical device and diagnostic field including executing multiple successful product development projects.
“Dr. Schoenbrunner has a proven track record of increasing innovation and productivity within diagnostic companies by planning and directing all aspects of the organization’s research and development initiatives,” said Brian Ward, Ph.D., diaDexus’ president and chief executive officer. “He will play a critical role on our team as we identify and develop our product pipeline opportunities.”
Most recently, Dr. Schoenbrunner was the vice president of research and development, molecular diagnostics for Life Technologies Corporation, a global biotechnology tools company where he helped to build R&D capabilities for IVD diagnostics. Dr. Schoenbrunner came to Life Technologies Corporation in 2010 as a key employee through the acquisition of AcroMetrix where he was the vice president of research and development. During his tenure at AcroMetrix, a privately held company and world market leader for nucleic acid testing quality and control materials, the company launched 30 new products. From 1992 to 2006, Dr. Schoenbrunner held various positions in the research department at Roche Diagnostics in Switzerland and Roche Molecular Systems Inc. in California, both world market leaders in diagnostics. Dr. Schoenbrunner was amongst others responsible for the development of a fully automated anti-HIV-1/2 assay and development of the first COBAS TaqMan HIV-1 Test. He studied at University of Regensburg where he got his Master of Science and also at the University of Edinburgh. He received his Ph.D. in Physical Biochemistry from the University of Bayreuth in Germany.
“It’s an exciting time to join the diaDexus team as they execute on the goal of creating a robust product pipeline,” Dr. Schoenbrunner said. “I look forward to being an active part of the team that identifies, develops and commercializes new cardiovascular products.”